Sarcoidosis from bench to bedside: A state-of-the-art series for the clinician

European Respiratory Journal

Volumn 40, Issue 1, 2012, Pages 14-16

  Cottin, Vincent ^a,b   Müller Quernheim, Joachim ^c  

^a LOUIS PRADEL HOSPITAL   (France)

^b UNIVERSITÉ LYON 1   (France)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BIOLOGICAL MARKER; CORTICOSTEROID; FLUORODEOXYGLUCOSE F 18; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE;

CHRONIC FATIGUE SYNDROME; CLINICAL FEATURE; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; EDITORIAL; ENVIRONMENTAL EXPOSURE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOPATHOGENESIS; LUNG BIOPSY; LUNG SARCOIDOSIS; LUNG TRANSPLANTATION; LYMPHADENOPATHY; MEDICAL LITERATURE; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCUPATIONAL EXPOSURE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

FATIGUE; HUMANS; SARCOIDOSIS;

EID: 84863480080     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00070712     Document Type: Editorial

References (31)

1. Iannuzzi MC, Fontana JR. Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. JAMA 2011; 305: 391-399.
2. Rybicki BA, Major M, Popovich J Jr, et al. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 1997; 145: 234-241.
3. Orphanet Report Series. Prevalence of rare disease: bibliographic data. Number 1. November 2011. www.orpha.net/orphacom/cahiers/docs/GB/Prevalence-of- rare-diseases-by-alphabetical-list.pdf
4. Gorham ED, Garland CF, Garland FC, et al. Trends and occupational associations in incidence of hospitalized pulmonary sarcoidosis and other lung diseases in navy personnel: a 27-year historical prospective study, 1975-2001. Chest 2004; 126: 1431-1438. (Pubitemid 39525013)
5. Kreider ME, Christie JD, Thompson B, et al. Relationship of environmental exposures to the clinical phenotype of sarcoidosis. Chest 2005; 128: 207-215. (Pubitemid 40994475)
6. Drent M, Wijnen PA, Boots AW, et al. Cat litter is a possible trigger for sarcoidosis. Eur Respir J 2012; 39: 221-222.
7. Rafnsson V, Ingimarsson O, Hjalmarsson I, et al. Association between exposure to crystalline silica and risk of sarcoidosis. Occup Environ Med 1998; 55: 657-660. (Pubitemid 28428962)
8. Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164: 1885-1889. (Pubitemid 33152325)
9. Statement on sarcoidosis. Joint statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS board of directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160: 736-755.
10. Herth FJ, Schuler H, Gompelmann D, et al. Endobronchial ultrasound-guided lymph node biopsy with transbronchial needle forceps: a pilot study. Eur Respir J 2012; 39: 373-377.
11. Braun JJ, Kessler R, Constantinesco A, et al. 18F-FDG PET/CT in sarcoidosis management: review and report of 20 cases. Eur J Nucl Med Mol Imaging 2008; 35: 1537-1543.
12. Teirstein AS, Machac J, Almeida O, et al. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest 2007; 132: 1949-1953.
13. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 1978; 58: 1204-1211. (Pubitemid 9092005)
14. Kim JS, Judson MA, Donnino R, et al. Cardiac sarcoidosis. Am Heart J 2009; 157: 9-21.
15. Marcellis RG, Lenssen AF, Elfferich MD, et al. Exercise capacity, muscle strength and fatigue in sarcoidosis. Eur Respir J 2011; 38: 628-634.
16. Drent M, Lower EE, De Vries J. Sarcoidosis-associated fatigue. Eur Respir J 2012; 40: 255-263.
17. Sahoo DH, Bandyopadhyay D, Xu M, et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur Respir J 2011; 38: 1145-1150.
18. Cottin V. Update on bioagent therapy in sarcoidosis. F1000 Med Rep 2010; 2: 13.
19. Shlobin OA, Nathan SD. Management of end-stage sarcoidosis: pulmonary hypertension and lung transplantation. Eur Respir J 2012; 39: 1521-1534.
20. Preston IR, Klinger JR, Landzberg MJ, et al. Vasoresponsivness of sarcoid-associated pulmonary hypertension. Chest 2001; 120: 866-872.
21. Baughman RP, Judson MA, Lower EE, et al. Inhaled iloprost for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26: 110-120.
22. Milman N, Burton CM, Iversen M, et al. Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil? J Heart Lung Transplant 2008; 75: 329-334. (Pubitemid 351375107)
23. Fisher KA, Serlin DM, Wilson KC, et al. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest 2006; 130: 1481-1488. (Pubitemid 44786743)
24. Barnett CF, Bonura EJ, Nathan SD, et al. Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience. Chest 2009; 135: 1455-1461.
25. Culver DA, Minai OA, Chapman JT, et al. Treatment of pulmonary hypertension in sarcoidosis. Proc Am Thoracic Soc 2005; 2: A862.
26. Baughman RP, Engel PJ, Taylor L, et al. Survival in sarcoidosis associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest 2010; 138: 1078-1085.
27. Judson MA, Ford HJ, Donohue JF, et al. Ambrisentan for sarcoidosis associated pulmonary hypertension. Am J Respir Crit Care 2010; 181: A2368.
28. Hofmann S, Fischer A, Till A, et al. A genome-wide association study reveals evidence of association with sarcoidosis at 6p12.1. Eur Respir J 2011; 38: 1127-1135.
29. Valentonyte R, Hampe J, Huse K, et al. Sarcoidosis is associated with a truncating splice site mutation in BTNL2. Nat Genet 2005; 37: 357-364.
30. Pabst S, Franken T, Schonau J, et al. Transforming growth factor-β gene polymorphisms in different phenotypes of sarcoidosis. Eur Respir J 2011; 38: 169-175.
31. Fischer A, Nothnagel M, Franke A, et al. Association of inflammatory bowel disease risk loci with sarcoidosis, and its acute and chronic subphenotypes. Eur Respir J 2011; 37: 610-616.